 |
|
|
|
|
Epilepsy Drug Linked to Bone Loss
Women on Dilantin may want to consider other seizure medications, experts say
By Amanda Gardner
HealthDay Reporter
|
| | | | Related Healthscout Videos | |
|
MONDAY, April 28 (HealthDay News) -- The epilepsy drug Dilantin may put young women who take it for a year or more at higher risk for osteoporosis, researchers report.
The bone loss described in a paper in the April 29 issue of Neurology was actually eight times higher than that experienced by premenopausal women who did not take any drugs for epilepsy.
Text Continues Below
"That suggests that if these women remain on this medication and have ongoing significant or accelerated bone loss that over time, they will be entering the peri-menopausal period with lower bone density and therefore a greater risk for low bone mineral density over time and therefore a higher risk of fractures," said study lead author Dr. Alison M. Pack, assistant professor of clinical neurology at Columbia University in New York City.
According to Dr. R. Eugene Ramsay, director of the International Center for Epilepsy at the University of Miami Miller School of Medicine, 90 percent of older people who have seizures are put on Dilantin, largely because it's inexpensive.
"It's particularly important, because the older population has the highest incidence of epilepsy. There are more new-onset seizures occurring there, and yet they are getting the cheapest and worst treatment," he said.
The findings are not entirely new, since previous research had already revealed an adverse effect on anti-epileptic drug treatment (Dilantin and other drugs) on bone and mineral metabolism. One previous study found that anti-seizure drugs had the same effect on the incidence of osteoporosis in older men as it did in older women, Ramsay said.
This study involved 93 premenopausal women (aged 18 to 40) with epilepsy, each of whom was taking either Dilantin (phenytoin), Tegretol (carbamazepine), Lamictal (lamotrigine) or Depakote (valproate).
The study was partially supported by GlaxoSmithKline, which makes Lamictal. Pack has also received funding from this and other pharmaceutical companies.
Page: 1 | 2 | Next >>
|
Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 4/28/2008
|
|
SOURCES: Alison M. Pack, M.D., assistant professor, clinical neurology, Columbia University, New York City; Steven V. Pacia, M.D., director, division of neurology, Lenox Hill Hospital, New York City; R. Eugene Ramsay, M.D., director, International Center for Epilepsy, University of Miami Miller School of Medicine; April 29, 2008, Neurology
|
.gif)
